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ABSTRACT
Recent studies have focused on issues related to heteroresistance, including its definition, methods of
detection and frequency. Most such studies have reported data concerning infections caused by
Staphylococcus aureus, but the clinical significance of heteroresistance is unclear. Six studies have
described infections caused by S. aureus strains that were heteroresistant to vancomycin, with two
suggesting an association between the emergence of heteroresistance and treatment failure or mortality,
and four suggesting no such association. Further studies are required to evaluate the clinical
implications of heteroresistance in an era in which rates of antimicrobial resistance are increasing
alarmingly worldwide.
Keywords Antibiotic resistance, clinical implications, glycopeptides, heteroresistance, Staphylococcus aureus,
vancomycin
Clin Microbiol Infect 2008; 14: 101–104
‘Heteroresistance’ is a widely used term, although
there is no distinct and precise definition that
encompasses this phenomenon in all microorgan-
isms. In broad terms, heteroresistance is defined as
resistance to certain antibiotics expressed by a
subset of a microbial population that is generally
considered to be susceptible to these antibiotics
according to traditional in-vitro susceptibility test-
ing. Various factors may subsequently lead to the
proliferation of the resistant sub-population and
the emergence of a fully resistant microbial strain.
The phenomenon of heteroresistance has been
observed in a range of microbes, including Staphy-
lococcus aureus, coagulase-negative staphylococci
[1], Acinetobacter baumannii [2], Mycobacterium
tuberculosis [3], Streptococcus pneumoniae [4], Entero-
coccus faecium [5] and Cryptococcus neoformans [6].
The frequency of heteroresistance, although this
differs among species, is about one sub-clone in
every 105–106 colonies, which roughly equals the
normal rate ofmutation. Heteroresistance could be
a tool for natural evolution to drug resistance, since
it provides bacteria with an opportunity to explore
the possibility of growth in the presence of antibi-
otics before acquisition of resistance by the major
proportion of the microbial population [4].
Heteroresistance is considered to be a precursor
stage, which may or may not lead to the emer-
gence of a resistant strain. Although this phe-
nomenon has been reproduced many times in the
laboratory setting, its clinical significance is
largely unknown. This is because it is only
possible to demonstrate the in-vitro resistance of
a strain to a particular antibiotic, and the patho-
genic potential of a strain for causing a clinical
infection is not yet understood. Bjorkman et al. [7]
described strains of Salmonella Typhimurium that
were resistant to several antibiotics in vitro, but
that were avirulent in vivo. These strains rapidly
regained their virulence, either following com-
pensatory mutations or by reversion to the anti-
biotic-susceptible virulent type, which occurs
to a varying extent in different environments.
Thus, the emergence of resistant strains in vitro
may not necessarily have therapeutic implica-
tions, since acquisition of resistance may be
accompanied by loss of virulence. Nevertheless,
heteroresistant strains have also been deemed to
be responsible for failure of prescribed treatment
[8,9]. Such clinical isolates can display certain
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characteristics, e.g., structure and morphology,
growth patterns and expression of genes, that
may play an important role in their virulence.
There are also cases in which the emergence of
heteroresistance to a particular antibiotic results
in increased resistance to other antimicrobial
agents [10]. For example, concerns have been
expressed regarding the spread of a clone of
methicillin-resistant S. aureus (MRSA) with het-
eroresistance to oxacillin in Dutch hospitals [11].
Until very recently, the phenomenon of hetero-
resistance was ignored or underestimated. How-
ever, several studies from various parts of the
world [12,13] have now provided estimates of the
prevalence of heteroresistant vancomycin-inter-
mediate S. aureus (hVISA), mainly among strains
of MRSA. There is a relative paucity of data
concerning the prevalence of heteroresistance in
other organisms, apart from a few case reports,
and current evidence regarding the clinical
importance of hVISA ⁄heteroresistant glycopep-
tide-intermediate S. aureus (hGISA) infections is
also scarce. Six studies concerning the clinical
significance of hGISA infections have been
described in the literature (Table 1), most of
which were retrospective and involved only a
small number of patients. In the majority of these
studies, the patients had bloodstream MRSA
infections in different clinical settings. Only two
studies [8,9] provided evidence suggesting that
MRSA carriers with hVISA strains may be more
prone to therapeutic failure, even after the use of
vancomycin. The four remaining studies did not
support this association; however, the numerous
methodological issues in the design of the studies
do not permit a definitive answer to this question.
The small number of patients studied who
yielded hVISA isolates, as well as a failure to
standardise the detection methods for heterore-
sistance, are also important limitations.
A further consideration is that definitive con-
clusions regarding an association between dosage
and duration of vancomycin treatment for MRSA
infection and the development of heteroresistance
cannot be reached from the available data. How-
ever, it is possible that prolonged exposure to
antimicrobial agents exerts increased pressure for
selection of microbial sub-populations that are
resistant to the therapy administered. According
to the mutant selection window hypothesis, there
is an antibiotic concentration above the MIC
(termed the mutation prevention concentration)
at which selective amplification of single-step,
drug-resistant mutants may occur [18]. Such
mutants may proliferate readily in the absence
of competition with the inhibited susceptible cells
of the wild-type strain, thereby giving rise to a
new resistant population with a higher MIC than
that for the wild-type strain. This observation has
implications for patients with infections at sites
where the penetration of antibiotics is sub-
optimal, despite an appropriate dosage scheme,
e.g., abscesses and endocardial vegetations [19].
A failure to detect MRSA isolates with reduced
susceptibility to glycopeptides could already be
contributing to a hidden spread of these strains
within hospital facilities. Methods for the
detection of such strains include determination
of a simplified population analysis profile (PAP)
on brain–heart infusion agar or Mueller–Hinton
agar, as well as the broth microdilution, agar
microdilution, Etest, PAP, agar disk-diffusion and
Microscan methods [12]. However, these methods
can be expensive, time-consuming or cumber-
some to perform routinely. Wootton et al. [20]
proposed that the macrodilution Etest should be
performed initially as a non-labour-intensive
screening method for a large number of isolates
that would generate few false-positive results. If
this method is considered too expensive, the
screening can be restricted to dialysis patients or
to patients receiving glycopeptides, who have a
greater probability of developing hGISA. Micro-
bial populations suspected of including heterore-
sistant sub-populations could then be subjected to
modified PAP analysis for a more accurate
assessment of their glycopeptide resistance status.
The same strategy could also be initiated, using
methods with higher sensitivity, for other organ-
isms, e.g., A. baumannii and M. tuberculosis, in
which there have been reports of the development
of heteroresistant strains [2,3].
Until the clinical significance of heteroresistant
strains has been investigated in greater detail,
several measures should be taken to prevent the
spread and ⁄ or emergence of these strains. First,
rigorous infection control policies, based on
agreed guidelines, should be instituted. Second,
the introduction of methods for rapid laboratory
detection of such strains should be considered to
enable early recognition and prevention of
spread. Third, antibiotics should be administered
with prudence. Shorter antimicrobial regi-
mens that are able to achieve the maximum
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effectiveness with the minimum selective pres-
sure should be further investigated. In-vitro stud-
ies have suggested that a combination of
antimicrobial agents may delay the emergence
of resistance [21]; however, meta-analyses of data
from randomised controlled studies have proved
inconclusive [22,23].
In conclusion, heteroresistance is increasingly
recognised, but is not a new phenomenon. Detec-
tion of heteroresistance is difficult, and there are
few laboratory or clinical data concerning this
subject. The clinical significance and therapeutic
implications of heteroresistance remain to be
determined. More relevant in-vitro, experimental
and clinical research data are urgently required.
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